Resources Repository
-
GuidelinesPublication 2011HPV Vaccine Introduction in LMIC's: Guidance on the Use of Cost-Effectiveness Models
This article is a literature review of HPV vaccination models suitable for low-income and middle-income …
This article is a literature review of HPV vaccination models suitable for low-income and middle-income country use to provide information about the feasibility of using such models in a developing country setting. The authors evaluated models in terms of their capacity, requirements, limitations and comparability. Their literature review identified six HPV vaccination models suitable for low-income and middle-income country use and representative of the literature in terms of provenance and model structure. Each model was…
Cost-Effectiveness Analysis | Health/Medicine | Global | Health Systems | Infectious Diseases | Mathematical Models | Calibration/Validation | Chronic Disease/Risk | Clinical Care | Science/Technology -
ArticlePublication 2010Clinical Benefits, Costs, and Cost-Effectiveness of Neonatal Intensive Care in Mexico
This article reports on a study to estimate the clinical outcomes, costs, and cost-effectiveness of …
This article reports on a study to estimate the clinical outcomes, costs, and cost-effectiveness of neonatal intensive care in Mexico. The authors conducted a cost-effectiveness analysis using a decision analytic model of health and economic outcomes following preterm birth. Model parameters governing health outcomes were estimated from Mexican vital registration and hospital discharge databases, supplemented with meta-analyses and systematic reviews from the published literature. Costs were estimated on the basis of data provided by the…
Cost-Effectiveness Analysis | Health/Medicine | Latin America & Caribbean | Health Systems | Child/Nutrition | State-Transition | Clinical Care -
ArticlePublication 2010Health and Economic Impact of Rotavirus Vaccination in GAVI-Eligible Countries
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately …
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Motivated by the global recommendation by the WHO that all countries include infant rotavirus vaccination in their national immunization programs, the objective of this analysis was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. The authors synthesized population-level data from various sources (primarily from…
Cost-Effectiveness Analysis | Health/Medicine | Latin America & Caribbean | Child/Nutrition | Infectious Diseases | Health Outcomes | Mathematical Models | State-Transition | Economics/Finance | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Cost-Effectiveness Analysis | Health/Medicine | Global | Child/Nutrition | Infectious Diseases | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Test Performance | Value of Information | State-Transition | Decision Analysis | Chronic Disease/Risk | Economics/Finance | North America | Europe | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
BriefPublication 2023Simulation Modeling to Guide Priority Setting in Global Maternal Health
This study developed the Global Maternal Health (GMatH) microsimulation model to evaluate maternal health policy …
This study developed the Global Maternal Health (GMatH) microsimulation model to evaluate maternal health policy interventions across 200 countries and territories from 1990 to 2050. It addresses challenges in measuring maternal mortality by simulating individual women's reproductive lifecycles. Various interventions, including family planning and facility-based care, were simulated to compare against a baseline scenario projecting the global maternal mortality ratio (MMR) to decrease to 167 per 100,000 live births by 2030. Results suggest that while…
Cost-Effectiveness Analysis | Health/Medicine | Global | Policy/Regulation | Microsimulation | Maternal/Reproductive Health -
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Cost-Effectiveness Analysis | Health/Medicine | Global | Policy/Regulation | Costing Methods | Health Outcomes | Evidence Synthesis | Decision Analysis | Benefit-Cost Analysis | Graduate | Doctoral | Professional -
ArticlePublication 2023Cost-Effectiveness of Novel TB Vaccines: A Modeling Study
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines …
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines in 105 low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies, compared to a ‘no-new-vaccine’ counterfactual. Vaccine scenarios considered two vaccine product profiles (one targeted at infants, one at adolescents/adults), both assumed to prevent progression to active TB. Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden.…
Cost-Effectiveness Analysis | Health/Medicine | Global | Infectious Diseases | Mathematical Models | Economics/Finance -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Cost-Effectiveness Analysis | Health/Medicine | Global | Infectious Diseases | Economics/Finance -
ArticlePublication 2022Re-Evaluating the Health Impact and Cost-Effectiveness of Tuberculosis Prevention for Modern ART Cohorts
TB preventive therapy (TPT) is widely accepted to be cost-effective for reducing TB incidence in …
TB preventive therapy (TPT) is widely accepted to be cost-effective for reducing TB incidence in HIV-infected individuals receiving antiretroviral therapy (ART). However, as individuals initiate ART earlier in the course of disease, TB incidence is lower, and it is unclear how ART cost-effectiveness has changed. This study assessed the cost-effectiveness of TPT in contemporary ART cohorts. The authors developed a microsimulation model of TB and HIV and parameterised it using data from a large HIV…
Cost-Effectiveness Analysis | Health/Medicine | Global | Infectious Diseases | Microsimulation | Sub-Saharan Africa